These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 35875937)

  • 21. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and
    Hagras M; Saleh MA; Ezz Eldin RR; Abuelkhir AA; Khidr EG; El-Husseiny AA; El-Mahdy HA; Elkaeed EB; Eissa IH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):380-396. PubMed ID: 34923885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2.
    Abd Elhameed AA; Ali AR; Ghabbour HA; Bayomi SM; El-Gohary NS
    Drug Dev Res; 2023 Dec; 84(8):1664-1698. PubMed ID: 37661648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition.
    El-Fakharany ZS; Nissan YM; Sedky NK; Arafa RK; Abou-Seri SM
    Sci Rep; 2023 Jul; 13(1):11346. PubMed ID: 37443185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking.
    Hassan RA; Hamed MIA; Abdou AM; El-Dash Y
    Bioorg Chem; 2022 Aug; 125():105861. PubMed ID: 35569190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates
    Eissa IH; El-Haggar R; Dahab MA; Ahmed MF; Mahdy HA; Alsantali RI; Elwan A; Masurier N; Fatahala SS
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1587-1599. PubMed ID: 35637622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers:
    Yousef RG; Elwan A; Gobaara IMM; Mehany ABM; Eldehna WM; El-Metwally SA; A Alsfouk B; Elkaeed EB; Metwaly AM; Eissa IH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2206-2222. PubMed ID: 35980113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducers.
    Eissa IH; Yousef RG; Elkady H; Elkaeed EB; Alsfouk AA; Husein DZ; Ibrahim IM; Elhendawy MA; Godfrey M; Metwaly AM
    Comput Biol Chem; 2023 Dec; 107():107953. PubMed ID: 37673011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
    Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
    Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.
    Hassan A; Badr M; Abdelhamid D; Hassan HA; Abourehab MAS; Abuo-Rahma GEA
    Bioorg Chem; 2022 Mar; 120():105631. PubMed ID: 35091289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
    El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-Phenylquinazolin-4(3H)-one scaffold as newly designed, synthesized VEGFR-2 allosteric inhibitors with potent cytotoxicity through apoptosis.
    Elrayess R; Elgawish MS; Nafie MS; Ghareb N; Yassen ASA
    Arch Pharm (Weinheim); 2023 Jun; 356(6):e2200654. PubMed ID: 37002183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
    Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
    Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
    Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel VEGFR-2 inhibitors as antiangiogenic and apoptotic agents via paracrine and autocrine cascades: Design, synthesis, and biological evaluation.
    Abdel Rahman DE; Fouad MA; Mohammed ER; El-Zoheiry HH; Abdelrasheed Allam H
    Bioorg Chem; 2023 Oct; 139():106678. PubMed ID: 37354661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
    Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
    Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
    El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
    Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.